scispace - formally typeset
E

Evelyn Nieves

Researcher at University of Michigan

Publications -  16
Citations -  906

Evelyn Nieves is an academic researcher from University of Michigan. The author has contributed to research in topics: Graft-versus-host disease & Antigen-presenting cell. The author has an hindex of 13, co-authored 16 publications receiving 862 citations. Previous affiliations of Evelyn Nieves include University of Illinois at Urbana–Champaign.

Papers
More filters
Journal ArticleDOI

Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality

TL;DR: A critical role for miR-142-3p in regulating DC responses to LPS is demonstrated and proof of concept for targeting miRs as a novel strategy for treatment of endotoxin-induced mortality is provided.
Journal ArticleDOI

Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

TL;DR: Administration of AAT early after BMT decreased mortality in three models of GvHD and reduced serum levels of proinflammatory cytokines in the allogeneic recipients compared with vehicle (albumin) treated animals, suggesting that AAT represents a novel unique and viable strategy to mitigate clinical Gv HD.
Journal ArticleDOI

Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic–derived antigen-presenting cells

TL;DR: The data suggest that infusion of sufficient numbers of alloreactive donor T cells will induce GVHD in the absence of radiosensitive host hematopoietic-derived APCs.
Journal ArticleDOI

Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells

TL;DR: In vivo administration of the histone methylation inhibitor 3-deazaneplanocin A (DZNep) arrests ongoing GVHD in mice after allogeneic BM transplantation and preserves the antileukemia activity of donor T cells and did not impair the recovery of hematopoiesis and lymphocytes, leading to significantly improved survival of recipients after allogenicic BM transplation.